Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab dose-escalation study in fistulizing Crohn's disease
ChiCTR2100049326Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab and azathioprine in Crohn's disease (3 arms), sponsored by Union Hospital. Primary endpoint: Fistula healing rate and recurrence rate. Started Aug 2021; status: recruiting.
02
Drugs
adalimumabazathioprine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2100049326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049326.